Developing novel ADC
treat high need cancers
Lead program: Nectin-4-targeting ADC – with potential across a range of hard to treat cancers.
Innovative linker and payload technology to deliver higher efficacy, lower risk of side effects and ability to avoid tumor resistance.
Antibodies with unique properties designed to lower both on-target and off-target side effects.
About UsRead More >
ScienceRead More >
ExecutionRead More >
PartnersRead More >
Financing enables company to embark on additional targets and expand ADC technology reach Duisburg, Germany – Marseille, France, 25 November 2020: Emergence Therapeutics AG, a European biopharmaceutical company developing novel antibody drug conjugate (ADC) immuno-therapeutics to treat high need cancers, announces that is has closed a Bumped-up Follow-on Seed Round Financing from a syndicate of...View Article >
Key Opinion Leaders bring many years of ADC development expertise to the company Duisburg, Germany - Marseille, France, 10 March 2020: Emergence Therapeutics today announced that is has established its Scientific Advisory Board (SAB) to support the company in its goal to develop novel and innovative antibody-drug-conjugates (ADCs).View Article >
Substantial experience in cancer targets, ADC technology as well as corporate finances and law Duisburg, Germany – Marseille, France, 22 January 2020: Emergence Therapeutics announced today that is has hired Florence Lhospice as Chief Development Officer and Carsten Dehning as Chief Financial Officer and member of the Executive Board to complement its management team. Dr....View Article >